Cell Therapeutics : FDA and ODAC to review $CTIC’s pixantrone and $CXSPY’s omacetaxine

CTIC

CTIC

This week, (10th February) the FDA’s Oncologic Drugs Advisory Committee will be meeting to review the filings from Cell Therapeutics ($CTIC) and ChemGenix ($CXSPY) for pixantrone and omacetaxine, in relapsed refractory NHL and CML, respectively.

I’ve just taken a few minutes to read the briefing documents and here are my initial thoughts.

Cell Therapeutics, a Seattle based biotech company, are going to have a very tough morning on Wednesday in DC for the following reasons:

1. The pivotal study had a very poor accrual with only 140 out of 320 patients enrolled.
2. Substantial cardiac and hematologic toxicities.

Risk:benefit trade-offs are always going to be a question for debate in the third-line setting, but CTI may well have shot themselves in the foot by closing enrollment early. This led the FDA to raise an important question about the study and whether there was sufficient information:

read full article: FDA and ODAC to review $CTIC’s pixantrone and $CXSPY’s omacetaxine
pharmastrategyblog.com

Related

Read Full Article

: Cell Therapeutics : FDA and ODAC to review $CTIC’s pixantrone and $CXSPY’s omacetaxine

Tags: , , , , , , , , , , , , , , , , , , , , , ,

http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/digg_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/reddit_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/dzone_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/stumbleupon_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/delicious_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/blinklist_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/blogmarks_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/furl_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/newsvine_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/technorati_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/magnolia_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/google_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/myspace_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/facebook_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/yahoobuzz_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/sphinn_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/mixx_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/twitter_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/jamespot_32.png http://www.usnewsdot.com/wp-content/plugins/sociofluid/images/meneame_32.png

Post On Feb 8th, 2010 and filed under Business, Health. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed.

3 Responses for “Cell Therapeutics : FDA and ODAC to review $CTIC’s pixantrone and $CXSPY’s omacetaxine”

  1. michael says:

    Why if heart failure is the effect of pixantrone don’t they use the heart strengthener?,cant remember the name of it right now-but it comes from a plant and strengthens the heart muscle oh digatalis is the name-of the heart strengthen chemical-it works from what I have heard-it really does work!Ben

  2. michael says:

    Could it be correct to assume Digitalis would be a good drug to use with Pixantrone-to help the heart stay stronger while the pixantrone effect this weakebing the heart?Ben

  3. michael says:

    Could it be correct to assume Digitalis would be a good drug to use with Pixantrone-to help the heart stay stronger while the pixantrone effect this weakening the heart?Ben

Comments are closed

Advertisement